# Kidney Precision Medicine Program (KPMP): Columbia AKI Recruitment Site

> **NIH NIH UH3** · COLUMBIA UNIVERSITY HEALTH SCIENCES · 2021 · $300,000

## Abstract

Project Summary (Abstract)
Our project brings together an experienced multidisciplinary team of clinical and basic scientist investigators at
Columbia University Medical Center with expertise in the fields of genetics, biomarkers, pathophysiology,
histopathology, renal biopsies, and therapy for kidney diseases to meet the aims of the Kidney Precision
Medicine Project (KPMP) Recruitment Site for acute kidney injury (AKI). Our primary objective in establishing
this site is to apply precision medicine techniques to patient biospecimens, including renal biopsies, and
longitudinal clinical data to understand the etiology of kidney damage and determine critical pathways that can
be targeted for therapy. The KPMP will occur in two phases: the UG3 exploratory phase and the UH3
expansion phase. Leveraging our existing inpatient nephrology consult services, we will create a multiethnic
cohort (including >50% enrollment of Latino and/or African-American subjects) of at least 200 patients with AKI
over five years. In the exploratory phase of the project, we will enroll at least 50 subjects over two years and
will standardize the collection of biospecimens from all study participants including blood, saliva, urine, stool,
and renal biopsy samples collected specifically for research purposes. The biospecimens will be pre-processed
for genetic, genomic, biomarker, and microbiome studies before the material is transferred to the KPMP
Central Hub. To track patient progress and outcomes, a longitudinal study protocol will be used consisting of
“dynamic” follow-up visits through electronic health records and yearly in-person visits. In addition, we will
share all extracted electronic health record data, survey data, and longitudinal clinical data from follow-up visits
from our participants with the larger KPMP initiative for collaborative purposes. In the expansion phase, we will
increase the cohort size by enrolling an additional 150 patients over three years and use KPMP consortium-
wide established protocols from the exploratory phase for biospecimen collection and longitudinal clinical data
collection. We will perform proof-of-concept studies with the longitudinal cohort of 200 Columbia patients with
AKI to determine a standard set of outcomes based on risk factors, known serum biomarkers, and genomic
data. Lastly, we will work with local kidney foundation chapters and community engagement experts to ensure
that the aims of the national KPMP are shared with the larger community so that participants understand the
importance of this initiative and the long-term benefits of continued study involvement. We expect that this
novel, tissue-based, mechanism-centered approach will challenge the traditional methods for diagnosing and
treating AKI and will contribute to the overall goals of the national KPMP.

## Key facts

- **NIH application ID:** 10223277
- **Project number:** 5UH3DK114926-05
- **Recipient organization:** COLUMBIA UNIVERSITY HEALTH SCIENCES
- **Principal Investigator:** JONATHAN M. BARASCH
- **Activity code:** UH3 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $300,000
- **Award type:** 5
- **Project period:** 2017-09-15 → 2023-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10223277

## Citation

> US National Institutes of Health, RePORTER application 10223277, Kidney Precision Medicine Program (KPMP): Columbia AKI Recruitment Site (5UH3DK114926-05). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10223277. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*